|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2004-5-20
|
|
pubmed:abstractText |
Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:BellDaphne WDW,
pubmed-author:BranniganBrian WBW,
pubmed-author:ChristianiDavid CDC,
pubmed-author:GurubhagavatulaSaradaS,
pubmed-author:HaberDaniel ADA,
pubmed-author:HaluskaFrank GFG,
pubmed-author:HarrisPatricia LPL,
pubmed-author:HaserlatSara MSM,
pubmed-author:LouisDavid NDN,
pubmed-author:LynchThomas JTJ,
pubmed-author:OkimotoRoss ARA,
pubmed-author:SettlemanJeffJ,
pubmed-author:SordellaRaffaellaR,
pubmed-author:SupkoJeffrey GJG
|
|
pubmed:copyrightInfo |
Copyright 2004 Massachusetts Medical Society
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
350
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2129-39
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15118073-Adenocarcinoma,
pubmed-meshheading:15118073-Adult,
pubmed-meshheading:15118073-Aged,
pubmed-meshheading:15118073-Aged, 80 and over,
pubmed-meshheading:15118073-Amino Acid Sequence,
pubmed-meshheading:15118073-Antineoplastic Agents,
pubmed-meshheading:15118073-Base Sequence,
pubmed-meshheading:15118073-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15118073-DNA Mutational Analysis,
pubmed-meshheading:15118073-Drug Resistance, Neoplasm,
pubmed-meshheading:15118073-Epidermal Growth Factor,
pubmed-meshheading:15118073-Female,
pubmed-meshheading:15118073-Genes, erbB-1,
pubmed-meshheading:15118073-Heterozygote,
pubmed-meshheading:15118073-Humans,
pubmed-meshheading:15118073-Lung Neoplasms,
pubmed-meshheading:15118073-Male,
pubmed-meshheading:15118073-Middle Aged,
pubmed-meshheading:15118073-Molecular Sequence Data,
pubmed-meshheading:15118073-Mutation,
pubmed-meshheading:15118073-Protein-Tyrosine Kinases,
pubmed-meshheading:15118073-Quinazolines,
pubmed-meshheading:15118073-Receptor, Epidermal Growth Factor,
pubmed-meshheading:15118073-Sequence Deletion
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
|
|
pubmed:affiliation |
Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
